Background
Dr. Forde treats patients with lung cancer, mesothelioma, and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently Co-Director of the Division of Upper Aerodigestive Malignancies in the Department of Oncology at Johns Hopkins and directs the multidisciplinary Thoracic Oncology Clinical Research Program.
He has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde's research examines the role of immunotherapy for mesothelioma and lung cancer and his work has led to the development of several ongoing phase 3 trials. In 2022, his work over several years, published in the New England Journal of Medicine, led to the FDA approval of neoadjuvant chemo-immunotherapy for the treatment of surgically operable lung cancer.
Dr. Forde serves as principal investigator for the thoracic cancer immunobiology biospecimen repository protocol at Johns Hopkins. He is focused on providing compassionate, state-of-the-art care for his patients in conjunction with a team of oncology specialist nurses, nurse practitioners, and dedicated staff.